{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:01:18Z","timestamp":1791601278271,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109693","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:11:06Z","timestamp":1771978266000},"page":"109693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives"],"prefix":"10.1016","volume":"174","author":[{"given":"Merve","family":"Zengin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem K.","family":"Arafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba T\u00fcyl\u00fc","family":"K\u00fc\u00e7\u00fckk\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oya Unsal","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bioorg.2026.109693_bb0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/wound.2013.0517","article-title":"Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair","volume":"3","author":"Johnson","year":"2014","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.bioorg.2026.109693_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2021.100422","article-title":"Tumor angiogenesis: current challenges and therapeutic opportunities","volume":"28","author":"Al-Ostoot","year":"2021","journal-title":"Cancer Treatment and Research Communications"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109693_bb0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies","volume":"13","author":"Liu","year":"2025","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109693_bb0020","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.3390\/ijms22073765","article-title":"Anti-angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109693_bb0025","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14-2023","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109693_bb0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","article-title":"Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer","volume":"31","author":"Masoumi Moghaddam","year":"2012","journal-title":"Cancer Metastasis Rev."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109693_bb0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109693_bb0040","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/1061186X.2025.2508985","article-title":"Revisiting VEGF\/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?","volume":"33","author":"Yao","year":"2025","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bioorg.2026.109693_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108231","article-title":"New indolin-2-ones, possessing sunitinib scaffold as HDAC inhibitors and anti-cancer agents with potential VEGFR inhibition activity; design, synthesis and biological evaluation","volume":"156","author":"Yousefian","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109693_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202405357","article-title":"2-indolinone: an anticancer scaffold, overview of the studies and approaches (2017\u20132024)","volume":"10","author":"Koulani","year":"2025","journal-title":"ChemistrySelect"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109693_bb0055","doi-asserted-by":"crossref","first-page":"2000022","DOI":"10.1002\/ardp.202000022","article-title":"Structure\u2013activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents","volume":"353","author":"Yousefian","year":"2020","journal-title":"Arch. Pharm."},{"issue":"11\u201312Suppl7","key":"10.1016\/j.bioorg.2026.109693_bb0060","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.5489\/cuaj.4296","article-title":"Sunitinib toxicity management - a practical approach","volume":"10","author":"Sehdev","year":"2016","journal-title":"Can. Urol. Assoc. J."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109693_bb0065","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/ph15111416","article-title":"Design, synthesis, molecular Modeling, and anticancer evaluation of new VEGFR-2 inhibitors based on the Indolin-2-one scaffold","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.109693_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108494","article-title":"Novel benzofuran-conjugated indolin-2-ones as anticancer agents; design, synthesis, biological assessments, and molecular modeling insights","volume":"160","author":"Eldehna","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"45","key":"10.1016\/j.bioorg.2026.109693_bb0075","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109693_bb0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Zaldini","year":"2010","journal-title":"Curr. Drug Targets"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109693_bb0085","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/molecules30051105","article-title":"Design, synthesis, and cytotoxicity evaluation of novel Indolin-2-one based molecules on hepatocellular carcinoma HepG2 cells as protein kinase inhibitors","volume":"30","author":"Kandeel","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109693_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107234","article-title":"New 2-oxoindole derivatives as multiple PDGFR\u03b1\/\u00df and VEGFR-2 tyrosine kinase inhibitors","volume":"145","author":"Ezelarab","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109693_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139839","article-title":"Design and synthesis of novel quinoxaline-piperazine linked isoxazole conjugates: anti-cancer assessment, tyrosine kinase EGFR inhibitory activity, molecular docking and DFT studies","volume":"1321","author":"Ravula","year":"2025","journal-title":"J. Mol. Struct."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109693_bb0100","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/ph17101320","article-title":"Arylpiperazine derivatives and Cancer: a new challenge in medicinal chemistry","volume":"17","author":"Andreozzi","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109693_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11094-022-02597-z","article-title":"Piperazine heterocycles as potential anticancer agents: a review","volume":"56","author":"Al-Ghorbani","year":"2022","journal-title":"Pharm. Chem. J."},{"issue":"17","key":"10.1016\/j.bioorg.2026.109693_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202405930","article-title":"Design and synthesis of some new indole-piperazine-1,2,3-triazole conjugates; in vitro anticancer, molecular docking, and ADMET studies","volume":"10","author":"Lingaswamy","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.109693_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2024.101025","article-title":"Iminium ion metabolites are formed from nintedanib by human CYP3A4","volume":"57","author":"Nakashima","year":"2024","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"24","key":"10.1016\/j.bioorg.2026.109693_bb0120","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1016\/j.bmc.2014.10.017","article-title":"Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents","volume":"22","author":"Chen","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109693_bb0125","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1039\/D0RA10672K","article-title":"Inversion kinetics of some E\/Z 3-(benzylidene)-2-oxo-indoline derivatives and their in silico CDK2 docking studies","volume":"11","author":"Mansour","year":"2021","journal-title":"RSC Adv."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109693_bb0130","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/ph17050659","article-title":"Discovery and anticancer screening of novel oxindole-based derivative bearing pyridyl group as potent and selective dual FLT3\/CDK2 kinase inhibitor","volume":"17","author":"Soudi","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109693_bb0135","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/febs.14756","article-title":"Metabolic reprogramming in breast cancer results in distinct mitochondrial bioenergetics between luminal and basal subtypes","volume":"286","author":"Lunetti","year":"2019","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109693_bb0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/metabo14080435","article-title":"Metabolic and oxidative stress management heterogeneity in a panel of breast Cancer cell lines","volume":"14","author":"Maycotte","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.bioorg.2026.109693_bb0145","article-title":"Breast cancer subtypes present a differential production of reactive oxygen species (ROS) and susceptibility to antioxidant treatment","volume":"9-2019","author":"Sarmiento-Salinas","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109693_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105708","article-title":"Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer","volume":"122","author":"Nafie","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109693_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.20892\/j.issn.2095-3941.2020.0151","article-title":"VEGFR2 inhibition hampers breast cancer cell proliferation <em>via<\/em> enhanced mitochondrial biogenesis","volume":"18","author":"Ni","year":"2021","journal-title":"Cancer Biology and Medicine"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109693_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202300115","article-title":"Absorption matters: a closer look at popular oral bioavailability rules for drug approvals","volume":"42","author":"Caminero Gomes Soares","year":"2023","journal-title":"Mol. Inform."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109693_bb0165","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11094-019-02000-4","article-title":"Design and synthesis of 2-Substitutedphenyl benzo[D]thiazole derivatives and their \u03b2-amyloid aggregation and cholinesterase inhibitory activities","volume":"53","author":"Zengin","year":"2019","journal-title":"Pharm. Chem. J."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.109693_bb0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109693_bb0175","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.109693_bb0180","series-title":"Dassault Syst\u00e8mes","author":"BIOVIA DS","year":"2021"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109693_bb0185","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109693_bb0190","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:02:31Z","timestamp":1777464151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S0045206826002294"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109693","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109693"}}